Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587001 · ClinicalTrials.gov registry record · NA
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
A NA study of Pulmonary Sarcoidosis, sponsored by National Jewish Health.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT01587001: Completed NA study of Pulmonary Sarcoidosis, sponsored by National Jewish Health.
NCT01587001 is a NA study of Pulmonary Sarcoidosis that has completed, run by National Jewish Health. The registered enrollment target is 17 participants, below the 812-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01587001, a NA study of Pulmonary Sarcoidosis, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
Primary Outcome
Baseline peripheral blood mononuclear cells and bronchoalveolar lavage (BAL) lymphocyte percentages and lipopolysaccharide (LPS) stimulated tumor necrosis factor-α levels (pg/ml)
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT N-acetyl-cysteine
Study Locations (1)
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-10 |
| Phase | NA |
What the finished NCT01587001 record still lists
NCT01587001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 812-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pulmonary Sarcoidosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01587001 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01587001 about?
NCT01587001 is a clinical study titled "The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis". This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
What is the current status of trial NCT01587001?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2011-11. Estimated completion is 2014-10.
What conditions does trial NCT01587001 study?
This clinical trial studies the following conditions: Pulmonary Sarcoidosis.
What interventions are being tested in trial NCT01587001?
The interventions under investigation include: Placebo (DRUG), N-acetyl-cysteine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01587001?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01587001 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
RECRUITING · Phase 1
-
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
RECRUITING · Phase 2
-
Role of Genetic Factors in the Development of Lung Disease
RECRUITING
-
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia